### [Lee et al. Page 1510][1] Immunotherap. with immune checkpoint inhibitors (ICI) has become a cornerstone of the clinical management of some tumor types, particularly those with high PD-L1 expression, an unstable genome, or high mutational burden. By contrast to ICI monotherapy, few biomarkers

中文翻译：

---

本期文章精选

### [李等人。第 1510 页][1] 免疫疗法。免疫检查点抑制剂 (ICI) 已成为某些肿瘤类型临床管理的基石，特别是那些具有高 PD-L1 表达、基因组不稳定或高突变负荷的肿瘤。与 ICI 单药治疗相比，很少有生物标志物